- Home
- GYRE vs ZYME Comparison
GYRE vs ZYME Comparison
Compare GYRE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- ZYME
- Stock Information
- Founded
- GYRE 2002
- ZYME 2003
- Country
- GYRE United States
- ZYME United States
- Employees
- GYRE N/A
- ZYME N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- GYRE Health Care
- ZYME Health Care
- Exchange
- GYRE Nasdaq
- ZYME Nasdaq
- Market Cap
- GYRE 897.1M
- ZYME 968.5M
- IPO Year
- GYRE N/A
- ZYME 2017
- Fundamental
- Price
- GYRE $7.90
- ZYME $15.93
- Analyst Decision
- GYRE Strong Buy
- ZYME Buy
- Analyst Count
- GYRE 1
- ZYME 7
- Target Price
- GYRE $18.00
- ZYME $20.00
- AVG Volume (30 Days)
- GYRE 96.3K
- ZYME 446.6K
- Earning Date
- GYRE 11-12-2025
- ZYME 10-30-2025
- Dividend Yield
- GYRE N/A
- ZYME N/A
- EPS Growth
- GYRE N/A
- ZYME N/A
- EPS
- GYRE 0.02
- ZYME N/A
- Revenue
- GYRE $102,189,000.00
- ZYME $122,867,000.00
- Revenue This Year
- GYRE $18.39
- ZYME $107.76
- Revenue Next Year
- GYRE $48.26
- ZYME $2.35
- P/E Ratio
- GYRE $469.46
- ZYME N/A
- Revenue Growth
- GYRE N/A
- ZYME 95.94
- 52 Week Low
- GYRE $6.11
- ZYME $9.03
- 52 Week High
- GYRE $19.00
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- GYRE 51.30
- ZYME 64.90
- Support Level
- GYRE $7.55
- ZYME $14.88
- Resistance Level
- GYRE $8.56
- ZYME $16.37
- Average True Range (ATR)
- GYRE 0.51
- ZYME 0.65
- MACD
- GYRE -0.01
- ZYME 0.11
- Stochastic Oscillator
- GYRE 57.14
- ZYME 84.12
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.